Boehringer Ingelheim

This study looks at how well the diabetes drug empagliflozin (Jardiance) works in everyday medical practice, outside of a controlled research setting. Researchers are comparing it to other diabetes medications in over 230,000 adults with type 2 diabetes. The goal is to see if the…

This study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for one year. Doctors track changes in the retina using specia…

This study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if …

This early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…

This study tests whether a new drug called vicadrostat, combined with the existing drug empagliflozin, can help adults with chronic kidney disease (CKD) that is at risk of getting worse. About 492 participants are randomly assigned to start both drugs at the same time or one afte…

This early-phase study tests a new drug, BI 1823911, alone or with another drug (BI 1701963), in people with advanced solid tumors that have a KRAS G12C mutation. The goal is to find a safe dose and see if the drugs can shrink tumors. About 30 adults with cancers like lung, color…

This early-stage study tests a new drug called BI 1701963, which blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not responded to prior chemotherapy. The m…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This study is tracking over 1,000 Japanese patients with chronic kidney disease who are taking JARDIANCE® (empagliflozin) daily for a long period. Researchers are monitoring side effects and whether the drug helps slow kidney decline in real-world conditions. The goal is to see i…

This study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It w…

This study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …

This study tests a new medicine called BI 764524, given as an eye injection, in 190 adults with moderate to severe diabetic retinopathy. Participants receive different numbers of injections over a year, and doctors check for eye improvements and side effects. The goal is to see i…

This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meanin…

This early-phase trial tests a new antibody-like drug called BI 764532 (Obrixtamig) combined with standard chemotherapy in about 69 adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find the highest safe dose of the …

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

This study tests whether survodutide, a weekly injection for weight loss, is safe for the heart in people who are overweight or obese and have heart or kidney disease. About 5,500 adults will receive either survodutide or a placebo for up to 2 years, along with diet and exercise …

This study tests a new daily pill, zongertinib, against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 mutation. About 428 adults who have not had prior treatment for advanced disease will be randomly assigned…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study tests a drug called BI 1291583 (Verducatib) in 268 adults with bronchiectasis, a lung condition that causes inflammation and infections. Participants take a low, medium, or high dose daily for up to a year. The goal is to see if the drug is safe and helps reduce sympto…

This study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This early-stage study tests a new medication, BI 3000202, in 16 adults with rare genetic conditions called type 1 interferonopathies (such as Aicardi-Goutières syndrome). The goal is to see if the drug is safe and how the body processes it. Participants take a low dose for 4 wee…

This early-phase study tests a new combination of two drugs, obrixtamig and ezabenlimab, in adults with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to prior treatments. The main goal is to find the highest safe dose of obrixtamig when gi…

This early-phase study tests a new drug, BI 764532, in adults with advanced brain tumors (glioma) that have a specific marker called DLL3. The drug works like a bridge, connecting cancer cells to immune cells to help the body fight the tumor. The main goal is to find the highest …

This early-stage trial tests a new daily pill, zongertinib, in adults with advanced cancers that have HER2 gene changes, including non-small cell lung cancer. The first part finds the safest dose; the second checks if it shrinks tumors. Participants stay on the drug as long as it…

This study looks at the long-term safety of the cancer drug brigimadlin in adults with solid tumors who have already received at least 4 cycles of the drug in a previous study. Participants take brigimadlin tablets once every 3 weeks at the study site. Doctors monitor their healt…

This early-phase study tests a new experimental drug, BI 765179, in adults with advanced solid tumors or head and neck cancer. The first part finds the safest dose when given alone or with another drug (ezabenlimab). The second part tests it with pembrolizumab in head and neck ca…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…

This study looks at how safe and effective the drug spesolimab is over nearly 5 years for people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study. The goal is to see if long-term tre…

This study looks at whether a new medicine called survodutide helps people with obesity burn more energy and fat compared to an existing drug, semaglutide. About 64 adults aged 18 to 65 with a BMI between 30 and 45 will receive weekly injections for several months. Researchers wi…

This early-stage trial tests whether a daily tablet called BI 1356225 can improve impulse control in people with opioid use disorder who are already taking buprenorphine. About 60 participants will be randomly assigned to receive either the study drug or a placebo for 8 days. Res…

This study tests a smartphone app called CT-155 designed to help people with schizophrenia manage negative symptoms like low motivation and reduced pleasure. About 262 adults with schizophrenia will use the app for 16 weeks, with an optional extension. Researchers will track symp…

This study observes nearly 8,000 patients with HER2-altered metastatic breast cancer in the US to see how they are treated in real-world settings and what their outcomes are. Researchers will look at treatment patterns, survival rates, and other factors from medical records. The …

This study looks at whether SGLT2 inhibitors, a type of diabetes drug, can help prevent or manage anemia in people with chronic kidney disease. Researchers will analyze data from 15,000 patients in Japan to see how these drugs affect anemia rates, treatments, and costs. The goal …

This study tests a new formulation of survodutide, a medicine being developed for obesity and liver conditions. About 100 healthy adults aged 18-65 with a BMI between 27 and 40 will receive weekly injections of either the current or new formula for 28 weeks. Researchers will meas…

This study collects blood samples from about 100 people with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will measure cancer DNA levels in the blood over time and compare them to tumor changes. The goal is…

This study analyzes health records from over 547,000 people in France who started taking SGLT2 inhibitors for type 2 diabetes between 2020 and 2024. Researchers will describe patient characteristics, prescription patterns, and track the occurrence of heart attacks, strokes, heart…

This study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …

This study monitors the long-term safety of the drug Ofev in people with lung disease caused by scleroderma. Researchers are tracking side effects like diarrhea and nausea in 586 patients in Japan who are starting Ofev for the first time. The goal is to see how common these side …

This study follows 5 people with cystic fibrosis who previously received a single dose of BI 3720931 gene therapy or placebo. No new treatment is given. Researchers will monitor participants for up to 15 years to check for long-term side effects and track lung function. The goal …

This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program, their quality of life, and any depression symptoms over 12 months. The goal is…